Long-Term Outcomes of Tisagenlecleucel in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
Lancet Oncol 2021 Sep 10;[EPub Ahead of Print], SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, EK Waller, S Jaglowski, MR Bishop, LE Damon, SR Foley, JR Westin, I Fleury, PJ Ho, S Mielke, T Teshima, M Janakiram, JM Hsu, K Izutsu, MJ Kersten, M Ghosh, N Wagner-Johnston, K Kato, P Corradini, M Martinez-Prieto, X Han, R Tiwari, G Salles, RT MaziarzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.